Published in Gene Therapy Weekly, December 26th, 2002
Avigen's lead product, Coagulin-B for the treatment of hemophilia B is currently in a phase I/II clinical trial, and the company expects to file an Investigation New Drug Application and enter the clinic with a treatment for Parkinson disease next year.
Pierce is an internationally recognized expert in gene therapy with 20 years experience in designing and managing preclinical research, clinical trials and academic collaborations in hemophilia, neurobiology, and tissue...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.